论文部分内容阅读
目的探讨肺癌细胞中多药耐药基因产物Ｐ－糖蛋白的表达与非小细胞肺癌预后的关系。方法１２６例非小细胞肺癌患者行手术切除加术后化疗，部分患者结合放疗。用免疫组织化学法检测手术标本中Ｐ－糖蛋白的表达。结果Ｐ－糖蛋白阳性表达者与阴性表达者其１～５年生存率无差异（Ｐ＞０．０５）；ＣＯＸ模型多因素分析显示Ｐ－糖蛋白的表达与肺癌预后无关（Ｐ＝０．８６３）。结论对于采用以手术为主综合治疗非小细胞肺癌患者，肺癌细胞Ｐ－糖蛋白的表达不能作为判断预后的指标
Objective To investigate the relationship between the expression of multidrug resistance gene product P-glycoprotein in lung cancer cells and the prognosis of non-small cell lung cancer. Methods One hundred and twenty-six patients with non-small cell lung cancer underwent surgical resection plus postoperative chemotherapy. Some patients were treated with radiotherapy. The expression of P-glycoprotein in surgical specimens was detected by immunohistochemistry. Results There was no difference in the 1- to 5-year survival rate between positive and negative P-glycoprotein expression (P>0.05). Multivariate analysis of COX model showed that the expression of P-glycoprotein was not related to the prognosis of lung cancer (P=0. 863). Conclusion The expression of P-glycoprotein in lung cancer cells cannot be used as an index to predict the prognosis of patients with non-small cell lung cancer treated with surgery.